Business

Annual Financial Report and Notice of AGM

Hikma Pharmaceuticals PLC has announced the availability of its 2025 Annual Report and Accounts, along with the Notice of the 2026 Annual General Meeting, both of which have been submitted to the National Storage Mechanism and are accessible on the company's website. Disclaimer*

articleHikma Pharmaceuticals PlcMarch 18, 20264/company/hikma-pharmaceuticals-plc/news/annual-financial-report-and-notice-of-agm-47
Annual Financial Report and Notice of AGM

About this update from Hikma Pharmaceuticals Plc

[{"type":"text","content":"\n\nHikma Pharmaceuticals PLC\n\n2025 Annual Report and Accounts and Notice of 2026 Annual General Meeting\n \nLONDON, 18 March 2026: Hikma Pharmaceuticals PLC (the \"Company\") announces that the Annual Report and Accounts for the year ended 31 December 2025 (the \"Annual Report\") and the Notice of the 2026 Annual General Meeting (the \"Notice of AGM\") are today being made available to shareholders.\nThe Annual Report and Notice of AGM can be viewed or downloaded from the Company's website at www.hikma.com/investors/2025-annual-report/.\nIn accordance with UK Listing Rule 6.4.1, copies of the Annual Report and Notice of AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.\n \n- ENDS -\n \n \n \n \nEnquiries\nHikma Pharmaceuticals PLC\n \nHelen Middlemist                                                                                                     +44 20 7399 2760\nGroup Company Secretary\n \n \n \n \nAbout Hikma\nHikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (rated BBB/stable S&P and BBB/stable Fitch)\nHikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide t...

More updates from Hikma Pharmaceuticals Plc